secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001682852-24-000057
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna Q3 net income $13M, revenue $1.9B; reiterates FY product sales $3-3.5B
------------------------------------------------------------------------------

- GAAP net income $13M ($0.03 EPS) vs net loss of $3.6B in Q3 2023; revenue $1.9B.
- Net product sales $1.8B (+4% YoY); COVID-19 sales $1.8B, RSV sales $10M (below expectations).
- FY 2024 product sales guidance reiterated at $3.0-3.5B; cost of sales guidance narrowed to 40-45%.
- R&D lowered to $4.6-4.7B; capex raised to ~$1.2B including Norwood campus purchase ($0.4B).
- Initiated Phase 3 trials for norovirus and influenza vaccines; expanded Executive Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285224000057/0001682852-24-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285224000057/mrna-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001682852-24-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer